|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/50 | |
| A61K 9/28 | |||
| A61K 31/506 | |||
| A61K 31/519 | |||
| A61K 9/48 |
| (11) | Number of the document | 3236953 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15826209.7 |
| Date of filing the European patent application | 2015-12-23 | |
| (97) | Date of publication of the European application | 2017-11-01 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-11 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/000303 |
| Date | 2015-12-23 |
| (87) | Number | WO 2016/105531 |
| Date | 2016-06-30 |
| (30) | Number | Date | Country code |
| 201462096809 P | 2014-12-24 | US |
| (72) |
NUNN, Philipp, US
BERNER, Bret, US
MASJEDIZADEH, Mohammad, US
|
| (73) |
Principia Biopharma Inc.,
220 E. Grand Ave., S. San Francisco, CA 94080,
US
|
| (54) | SITE SPECIFIC DOSING OF A BTK INHIBITOR |
| SITE SPECIFIC DOSING OF A BTK INHIBITOR |